Haroldsen, Anne |
| Active, not recruiting | 2/3 | 186 | NA | Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 05/25 | 05/25 | | |
| Recruiting | 1 | 36 | US | Microbial Transplant Therapy, fecal transplant, Placebo | Joshua Stern, University of Minnesota, Albert Einstein College of Medicine, Litholink Corporation | Kidney Stones | 12/26 | 03/27 | | |
PROGRESS, NCT05612750: Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The Study |
|
|
| Recruiting | N/A | 1200 | US | Education | Stanford University, Patient-Centered Outcomes Research Institute | Pain, Chronic | 05/28 | 05/28 | | |
| Not yet recruiting | N/A | 260 | US | Surveys | Intermountain Health Care, Inc., Regeneron Pharmaceuticals | Post-acute COVID-19 (PACS), or "Long COVID" Syndrome | 02/22 | 04/22 | | |
Hossain, Zakir |
| Active, not recruiting | 2/3 | 186 | NA | Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 05/25 | 05/25 | | |
Unsworth, Anika |
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis |
|
|
| Recruiting | 3 | 150 | NA | Saroglitazar Magnesium 1 mg | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 04/27 | 07/27 | | |